Joseph Vijai
Overview
Explore the profile of Joseph Vijai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
6765
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stopsack K, Vijai J, Conry M, Berchuck J, Kemel Y, Vasselman S, et al.
Clin Cancer Res
. 2024 Oct;
31(1):122-129.
PMID: 39450704
Purpose: Deleterious germline variants in certain DNA repair genes are risk factors for developing aggressive prostate cancer. The objective was to quantify their prognostic impact after prostate cancer diagnosis. Experimental...
2.
Mabey B, Hughes E, Kucera M, Simmons T, Hullinger B, Pederson H, et al.
Genet Med
. 2024 Jun;
26(7):101128.
PMID: 38829299
Purpose: We previously described a combined risk score (CRS) that integrates a multiple-ancestry polygenic risk score (MA-PRS) with the Tyrer-Cuzick (TC) model to assess breast cancer (BC) risk. Here, we...
3.
Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus G, et al.
Sci Rep
. 2023 Nov;
13(1):20567.
PMID: 37996508
Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair (NER)...
4.
Berndt S, Vijai J, Benavente Y, Camp N, Nieters A, Wang Z, et al.
Leukemia
. 2023 Sep;
37(10):2142.
PMID: 37666943
No abstract available.
5.
Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T, et al.
J Med Genet
. 2023 Jul;
60(12):1186-1197.
PMID: 37451831
Background: Polygenic risk score (PRS), calculated based on genome-wide association studies (GWASs), can improve breast cancer (BC) risk assessment. To date, most BC GWASs have been performed in individuals of...
6.
Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus G, et al.
bioRxiv
. 2023 Feb;
PMID: 36798363
Purpose: Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair...
7.
Mueller S, Lai A, Valkovskaya M, Michailidou K, Bolla M, Wang Q, et al.
Genome Med
. 2023 Jan;
15(1):7.
PMID: 36703164
Background: Low-frequency variants play an important role in breast cancer (BC) susceptibility. Gene-based methods can increase power by combining multiple variants in the same gene and help identify target genes....
8.
Belhadj S, Khurram A, Bandlamudi C, Palou-Marquez G, Ravichandran V, Steinsnyder Z, et al.
Clin Cancer Res
. 2022 Nov;
29(2):422-431.
PMID: 36346689
Purpose: To explore the role of NBN as a pan-cancer susceptibility gene. Experimental Design: Matched germline and somatic DNA samples from 34,046 patients were sequenced using Memorial Sloan Kettering-Integrated Mutation...
9.
Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200084.
PMID: 36331239
Purpose: Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. Their application to women of non-European ancestry has lagged because...
10.
Berndt S, Vijai J, Benavente Y, Camp N, Nieters A, Wang Z, et al.
Leukemia
. 2022 Oct;
36(12):2835-2844.
PMID: 36273105
Lymphoma risk is elevated for relatives with common non-Hodgkin lymphoma (NHL) subtypes, suggesting shared genetic susceptibility across subtypes. To evaluate the extent of mutual heritability among NHL subtypes and discover...